Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19205170 | NOVEL CYTOKINE-BASED THERAPIES AND METHODS | May 2025 | February 2026 | Allow | 10 | 1 | 1 | No | No |
| 18002881 | ANTI-RSV ANTIBODY AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | December 2022 | August 2025 | Allow | 31 | 0 | 0 | No | No |
| 17998642 | ANTI-OSCAR ANTIBODY FOR PREVENTING OR TREATING OSTEOARTHRITIS | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 17914027 | CD28H DOMAIN-CONTAINING CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | September 2022 | March 2026 | Allow | 42 | 1 | 1 | Yes | No |
| 17620064 | COMPOSITIONS AND ARTICLES COMPRISING (NANO)DIAMOND PARTICLES | August 2022 | December 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17759854 | HUMAN BLOOD-BRAIN BARRIER TARGETING ANTIBODIES | July 2022 | August 2025 | Allow | 36 | 0 | 1 | No | No |
| 17638453 | METHOD FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME USING AN INHIBITORY OR CYTOTOXIC AGENT AGAINST PLASMA CELLS | February 2022 | December 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17621711 | TNF MUTEINS AND USES THEREOF | December 2021 | December 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17442072 | ANTI-HER2 BINDING MOLECULES | September 2021 | August 2025 | Allow | 46 | 1 | 1 | No | No |
| 17051860 | T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR | October 2020 | November 2025 | Allow | 60 | 3 | 1 | No | No |
| 16975431 | RAPID AND SIMPLE PURIFICATION OF ELASTIN-LIKE POLYPEPTIDES DIRECTLY FROM WHOLE CELLS AND CELL LYSATES BY ORGANIC SOLVENT EXTRACTION | August 2020 | February 2026 | Allow | 60 | 2 | 0 | Yes | No |
| 13757655 | BACTERIOPHAGE-CONTAINING THERAPEUTIC AGENTS | February 2013 | February 2017 | Allow | 49 | 3 | 1 | Yes | No |
| 11266444 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN | November 2005 | March 2009 | Allow | 41 | 2 | 1 | No | No |
| 10300247 | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CPG DINUCLEOTIDE AS AN ADJUVANT | November 2002 | February 2012 | Allow | 60 | 9 | 1 | No | No |
| 09880748 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND BLYS | June 2001 | December 2005 | Allow | 54 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner NICKOL, GARY B works in Art Unit 1643 and has examined 9 patent applications in our dataset. With an allowance rate of 88.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 49 months.
Examiner NICKOL, GARY B's allowance rate of 88.9% places them in the 70% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by NICKOL, GARY B receive 2.67 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NICKOL, GARY B is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +20.0% benefit to allowance rate for applications examined by NICKOL, GARY B. This interview benefit is in the 63% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.